<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550628</url>
  </required_header>
  <id_info>
    <org_study_id>07-114</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-07114</secondary_id>
    <nct_id>NCT00550628</nct_id>
  </id_info>
  <brief_title>Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer</brief_title>
  <official_title>Pilot Study of Ex-Vivo Molecular Polyp Imaging Using 18-F Fluorodeoxyglucose (FGD) Positron Emission Tomography (PET) in the Determination of Protein and Gene Expression Signatures of Premalignant Polyps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic imaging procedures, such as fludeoxyglucose F 18 PET, may be effective
      in detecting cancer or recurrence of cancer, or premalignant polyps.

      PURPOSE: This clinical trial is studying fludeoxyglucose F 18-PET imaging to see how well it
      works in determining protein and gene expression signatures in patients with premalignant
      polyps or colon cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the feasibility of ex-vivo imaging of colon cancer and colon polyps using
           fludeoxyglucose F 18 positron emission tomography (FDG PET).

        -  To evaluate the differences in molecular and genetic profiles between FDG-positive
           polyps and FDG-negative polyps to suggest what gene mutations and abnormal mRNA and/or
           protein expressions may be required for FDG avidity (&quot;signature&quot; for FDG avidity).

      Secondary

        -  To evaluate the differences in molecular and genetic profiles between FDG-positive
           polyps and FDG-positive cancers to suggest what gene mutations and abnormal mRNA and/or
           protein expressions may be required for cancer formation (&quot;signature&quot; for cancer).

        -  To evaluate the differences in molecular and genetic profiles between normal colonic
           mucosa, polyps, and cancer.

        -  To evaluate the differences and similarities in molecular and genetic profiles between
           FDG-positive cancers and polyps.

      OUTLINE: Part I: Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later
      by surgery to remove part or all of the colon. Tissue samples of the colon undergo positron
      emission tomography (PET) imaging.

      Part II: Tissue samples are analyzed for glucose transporters proteins (Glut-1, 2, 3, 4, 5,
      7) via IHC; presence of K-ras mutation (invariable mutant site on codon 12, 13) via PCR; 18q
      deletion via fluorescence in situ hybridization (FISH) or DCC IHC; MCT-1, Hex-1, Hex-2, and
      COX-2 expression levels via quantitative RT-PCR method or western blot; APC mutation via PCR-
      In Vitro Synthesized-Protein Assay or RT-PCR direct sequencing method; p53 mutation detection
      via immunochemistry, RT-PCR direct sequence methods, and western blot; methylation alteration
      of MGMT, CDKN2A, HLTF, MLH1, TIMP3, HIF1, BNIP3, and HRK via methylation detecting microchip;
      and specific gene methylations via methylation-specific PCR. Some tissue samples may be saved
      and banked for future studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of ex-vivo imaging of colon cancer and colon polyps using fludeoxyglucose F 18 positron emission tomography (FDG PET)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in molecular and genetic profiles between FDG-positive polyps and FDG-negative polyps to suggest what gene mutations and abnormal mRNA and/or protein expressions may be required for FDG avidity (&quot;signature&quot; for FDG avidity)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in molecular and genetic profiles between FDG-positive polyps and FDG-positive cancers to suggest what gene mutations and abnormal mRNA and/or protein expressions may be required for cancer formation (&quot;signature&quot; for cancer)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in molecular and genetic profiles between normal colonic mucosa, polyps, and cancer</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences and similarities in molecular and genetic profiles between FDG-positive cancers and polyps</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Neoplasm of Uncertain Malignant Potential</condition>
  <arm_group>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
    <description>The surgically removed colon will undergo ex-vivo imaging after examination in pathology. A PET scanner will be used to acquire a scan of the whole specimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA methylation analysis</intervention_name>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <arm_group_label>resection of a non-sarcomatous primary colon neoplasm</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        MSK clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Subject Inclusion Criteria:

          -  Patients eligible for entry into the study are those:

          -  Age 15 to 100

          -  Undergoing resection of a non-sarcomatous primary colon neoplasm who also has 2 or
             more adenomas each greater than or equal to 7-10mm in size which are anticipated to be
             removed with the colon specimen.

          -  It will be known from MSKCC or outside studies (barium enema, endoscopy, PET/CT, or CT
             colonography) that the patient has at least 2 proven adenomas 7-10 mm or greater and a
             primary colon neoplasm

        Subject Exclusion Criteria:

          -  Insulin-dependent diabetics (as established by routine history and presurgical
             laboratory tests).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc J. Gollub, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suresh Jhanwar, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoplasm of uncertain malignant potential</keyword>
  <keyword>colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

